Immunoglobulin Light-chain Amyloidosis
Immunoglobulin Light-chain Amyloidosis
Explore linked clinical trials. Standard reference: MESH:M00063023868 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT05451771 | |
| Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 2 | 2026-10-01 | NCT05898646 | |
| SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-09-30 | NCT07850284 | |
| BE.Amycon Biobank & Data Registry UZ Leuven | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, immune system disorder, immunoproliferative disorder, inborn errors of metabolism, inherited neurodegenerative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Not stated | 2026-09-25 | NCT07172243 | |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, proteostasis deficiencies, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-25 | NCT06768489 | |
| A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Not applicable | 2026-09-16 | NCT07215494 | |
| Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, immune system disorder, immunoproliferative disorder, inborn errors of metabolism, inherited neurodegenerative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, plasma cell neoplasm, proteostasis deficiencies | Enrolling by invitation | Not stated | 2026-09-10 | NCT07103863 | |
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Phase 3 | 2026-08-28 | NCT07793422 | |
| A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Early phase 1 | 2026-08-21 | NCT07615270 | |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT06569147 | |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT05145816 | |
| PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, immune system disorder, immunoproliferative disorder, inborn errors of metabolism, inherited neurodegenerative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, plasma cell neoplasm, proteostasis deficiencies | Enrolling by invitation | Phase 1 | 2026-08-18 | NCT07771621 | |
| A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-14 | NCT07765524 | |
| 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, central nervous system cancer, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, nervous system disorder, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Not stated | 2026-08-10 | NCT00935090 | |
| BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Phase 2 | 2026-08-07 | NCT07751471 | |
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Phase 2 | 2026-08-05 | NCT07524634 | |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-08-03 | NCT07638683 | |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 1 | 2026-07-31 | NCT04847453 | |
| Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 2 | 2026-07-28 | NCT07335887 | |
| A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, primary systemic amyloidosis, proteostasis deficiencies | Recruiting | Phase 1 | 2026-07-24 | NCT05951816 | |
| Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 | 2026-07-23 | NCT07250269 | |
| The Norwegian Immunotherapy in Multiple Myeloma Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Infections, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell leukemia, plasma cell myeloma, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-07-20 | NCT06855121 | |
| A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 2 | 2026-07-20 | NCT06649695 | |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 2 | 2026-07-17 | NCT07224672 | |
| Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT06097832 |